P30AI161943

Texas Developmental Center for AIDS Research - Project Summary

In 2019, the US announced a plan to end the HIV epidemic by 2030. To be successful, strategies that improve HIV prevention and HIV treatment outcomes are needed. Only 56% of people with HIV (PWH) were virally suppressed in 2018, a critical determinant of health outcomes and transmission risk. Additionally, 51% of HIV diagnoses in 2018 were in the US South, despite constituting only 38% of the population in the US.

Texas, the second most populous state in the US, with about 29 million residents, is in the US South as defined by CDC and the Census Bureau. Unfortunately, this large Texas population, coupled with weaker public health and prevention policies and funding across the US South, has a growing HIV population that lags in critical health outcomes. There is an urgent need for more research and research infrastructure to combat the HIV epidemic in the US South and specifically in Texas, both to contribute to ending the US HIV epidemic and to learn how to best do that in resource-constrained areas of the US.

We, therefore, will establish a Texas Developmental Center for AIDS Research (D-CFAR) to support the overall mission of the National CFAR Program by facilitating high-priority HIV research and supporting the effort to end the HIV epidemic in the US. Three institutions have collaborated to propose this D-CFAR: Baylor College of Medicine in Houston, the University of Texas Health Science Center at Houston, and the Texas Biomedical Research Institute in San Antonio.

Based upon the outstanding expertise of its investigators, the Texas D-CFAR will focus its activities in the five-year funding period on the research theme "Ending HIV and Optimizing HIV Health in Texas." To accomplish its goals, the Texas D-CFAR will:

1) Provide organizational and financial management and facilitate activities and programs that strengthen and enrich the D-CFAR research and intellectual environment.

2) Support targeted high-priority interdisciplinary pilot research projects, assist in responding to new HIV-related research initiatives, and facilitate research on ending HIV and improving the health of PWH in Texas.

3) Provide state-of-the-art expertise, advice, and services to facilitate the range of HIV-related research for D-CFAR investigators.

The Texas D-CFAR will support an Administrative Core, a Developmental Core, a Basic Science Core, and a Clinical and Biostatistics Core to meet investigator needs and catalyze innovative research. The scientific cores will build on outstanding strengths in virology, non-human primate resources, clinical trials research, and biostatistics. The D-CFAR will engage a Community Advisory Board and internal and external advisory boards for guidance.

Coupled with outstanding institutional support, the D-CFAR will stimulate new research and collaborations among basic, translational, clinical, health services, and public health researchers. The D-CFAR will significantly advance knowledge needed to end HIV and improve the health of PWH in Texas and similar areas, train the next generation of scientists, and grow into a full CFAR, thereby contributing to ending the HIV epidemic in Texas, the US South, and beyond.

Baylor College Of Medicine

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.279 - Drug Abuse and Addiction Research Programs

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

National Institute on Drug Abuse (NIDA) [HHS - NIH]

Houston, Texas 770303411 United States

Single Zip Code

Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed) (PAR-20-107)

Amendment Since initial award the total obligations have increased 34950% from $23,630 to $8,282,292.